[Form 4] PROCEPT BioRobotics Corporation Insider Trading Activity
The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.
La comunicazione indica che Antal Rohit Desai, direttore di PROCEPT BioRobotics (PRCT), ha esercitato opzioni su azioni acquisendo 26.749 azioni il 14/08/2025 a un prezzo di esercizio in contanti di $1.33 per azione. Dopo la transazione detiene beneficiariamente in totale 35.152 azioni, comprese 14.363 azioni detenute indirettamente da The 2:22 DNA Trust. L'opzione esercitata era completamente maturata ed esercitabile, e l'esercizio è avvenuto in contanti. Il Modulo 4 è stato firmato da un mandatario per procura in nome del Sig. Desai il 15/08/2025.
La presentación muestra que Antal Rohit Desai, director de PROCEPT BioRobotics (PRCT), ejerció opciones sobre acciones y adquirió 26.749 acciones el 14/08/2025 a un precio de ejercicio en efectivo de $1.33 por acción. Tras la operación posee beneficiariamente un total de 35.152 acciones, incluidas 14.363 acciones mantenidas indirectamente por The 2:22 DNA Trust. La opción ejercida estaba totalmente consolidada y era ejercitable, y el ejercicio se realizó en efectivo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Desai el 15/08/2025.
서류에 따르면 PROCEPT BioRobotics(PRCT)의 이사인 Antal Rohit Desai는 스톡옵션을 행사하여 2025년 8월 14일 주당 $1.33의 현금 행사가로 26,749주를 취득했습니다. 거래 후 그는 총 35,152주를 실질적으로 보유하게 되었으며, 그중 14,363주는 The 2:22 DNA Trust를 통해 간접 보유하고 있습니다. 행사된 옵션은 완전히 베스팅되어 행사 가능했으며, 행사는 현금으로 이루어졌습니다. Form 4는 2025년 8월 15일 Desai 씨를 대신한 대리인이 서명했습니다.
Le dépôt indique qu'Antal Rohit Desai, administrateur de PROCEPT BioRobotics (PRCT), a exercé des options sur actions et acquis 26 749 actions le 14/08/2025 au prix d'exercice en espèces de $1.33 par action. Après la transaction, il détient bénéficiairement au total 35 152 actions, dont 14 363 détenues indirectement par The 2:22 DNA Trust. L'option exercée était entièrement acquise et exerçable, et l'exercice a été effectué en espèces. Le formulaire 4 a été signé le 15/08/2025 par un mandataire ayant procuration au nom de M. Desai.
Die Einreichung zeigt, dass Antal Rohit Desai, ein Direktor von PROCEPT BioRobotics (PRCT), Aktienoptionen ausgeübt und am 14.08.2025 26.749 Aktien zu einem Barausübungspreis von $1.33 je Aktie erworben hat. Nach der Transaktion besitzt er wirtschaftlich insgesamt 35.152 Aktien, darunter 14.363 Aktien, die indirekt von The 2:22 DNA Trust gehalten werden. Die ausgeübte Option war vollständig unverfallbar und ausübbar, und die Ausübung erfolgte in bar. Das Formular 4 wurde am 15.08.2025 von einem Bevollmächtigten im Namen von Herrn Desai unterzeichnet.
- Director increased ownership by exercising 26,749 options, raising beneficial holdings to 35,152 shares.
- Options were fully vested and exercisable, and the exercise was completed as a cash transaction at $1.33 per share.
- None.
Insights
TL;DR: Director exercised fully vested options to acquire 26,749 shares at $1.33, modestly increasing insider ownership.
The transaction is a routine insider option exercise rather than an open-market purchase or sale. A cash exercise of 26,749 options increases total reported beneficial ownership to 35,152 shares, with 14,363 shares held indirectly through a trust. For investors this is a limited, non-dilutive transfer from option to common stock that does not change company cash flow materially beyond the exercise proceeds.
TL;DR: This Form 4 documents a standard, fully vested option exercise by a director; disclosure appears complete and timely.
The filing identifies the reporter as a director and indicates the option was fully vested and exercised for cash. Reporting was done on a single-person Form 4 and signed by an attorney-in-fact. No additional derivative holdings remain for the reporter post-transaction. From a governance and disclosure standpoint, the Form 4 provides the required details: dates, quantities, price, and ownership form.
La comunicazione indica che Antal Rohit Desai, direttore di PROCEPT BioRobotics (PRCT), ha esercitato opzioni su azioni acquisendo 26.749 azioni il 14/08/2025 a un prezzo di esercizio in contanti di $1.33 per azione. Dopo la transazione detiene beneficiariamente in totale 35.152 azioni, comprese 14.363 azioni detenute indirettamente da The 2:22 DNA Trust. L'opzione esercitata era completamente maturata ed esercitabile, e l'esercizio è avvenuto in contanti. Il Modulo 4 è stato firmato da un mandatario per procura in nome del Sig. Desai il 15/08/2025.
La presentación muestra que Antal Rohit Desai, director de PROCEPT BioRobotics (PRCT), ejerció opciones sobre acciones y adquirió 26.749 acciones el 14/08/2025 a un precio de ejercicio en efectivo de $1.33 por acción. Tras la operación posee beneficiariamente un total de 35.152 acciones, incluidas 14.363 acciones mantenidas indirectamente por The 2:22 DNA Trust. La opción ejercida estaba totalmente consolidada y era ejercitable, y el ejercicio se realizó en efectivo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Desai el 15/08/2025.
서류에 따르면 PROCEPT BioRobotics(PRCT)의 이사인 Antal Rohit Desai는 스톡옵션을 행사하여 2025년 8월 14일 주당 $1.33의 현금 행사가로 26,749주를 취득했습니다. 거래 후 그는 총 35,152주를 실질적으로 보유하게 되었으며, 그중 14,363주는 The 2:22 DNA Trust를 통해 간접 보유하고 있습니다. 행사된 옵션은 완전히 베스팅되어 행사 가능했으며, 행사는 현금으로 이루어졌습니다. Form 4는 2025년 8월 15일 Desai 씨를 대신한 대리인이 서명했습니다.
Le dépôt indique qu'Antal Rohit Desai, administrateur de PROCEPT BioRobotics (PRCT), a exercé des options sur actions et acquis 26 749 actions le 14/08/2025 au prix d'exercice en espèces de $1.33 par action. Après la transaction, il détient bénéficiairement au total 35 152 actions, dont 14 363 détenues indirectement par The 2:22 DNA Trust. L'option exercée était entièrement acquise et exerçable, et l'exercice a été effectué en espèces. Le formulaire 4 a été signé le 15/08/2025 par un mandataire ayant procuration au nom de M. Desai.
Die Einreichung zeigt, dass Antal Rohit Desai, ein Direktor von PROCEPT BioRobotics (PRCT), Aktienoptionen ausgeübt und am 14.08.2025 26.749 Aktien zu einem Barausübungspreis von $1.33 je Aktie erworben hat. Nach der Transaktion besitzt er wirtschaftlich insgesamt 35.152 Aktien, darunter 14.363 Aktien, die indirekt von The 2:22 DNA Trust gehalten werden. Die ausgeübte Option war vollständig unverfallbar und ausübbar, und die Ausübung erfolgte in bar. Das Formular 4 wurde am 15.08.2025 von einem Bevollmächtigten im Namen von Herrn Desai unterzeichnet.